DDInter704 DDInter51
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Alogliptin
Everolimus {u} (Compound) causes {v} (Side Effect) Pancreatitis
Pancreatitis {u} (Side Effect) is caused by {v} (Compound) Alogliptin
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Linagliptin
Linagliptin {u} (Compound) resembles {v} (Compound) Alogliptin
Everolimus {u} (Compound) causes {v} (Side Effect) Pancreatitis
Pancreatitis {u} (Side Effect) is caused by {v} (Compound) Linagliptin
Linagliptin {u} (Compound) resembles {v} (Compound) Alogliptin
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Linagliptin
Linagliptin {u} (Compound) resembles {v} (Compound) Alogliptin
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nelfinavir
Nelfinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Everolimus {u} (Compound) causes {v} (Side Effect) Pancreatitis
Pancreatitis {u} (Side Effect) is caused by {v} (Compound) Hydrochlorothiazide
Hydrochlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alogliptin
Everolimus {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Alogliptin
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Alogliptin
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound)
Everolimus (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Alogliptin (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound) and Linagliptin (Compound) resembles Alogliptin (Compound)
Everolimus (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Linagliptin (Compound) and Linagliptin (Compound) resembles Alogliptin (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nelfinavir (Compound) and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Everolimus (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin
Everolimus (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Alogliptin
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound)